Opthea Cuts 65% Staff, Terminates Drug Trials

MT Newswires Live2025-04-10

Opthea (ASX:OPT) has terminated phase three clinical trials for two of its drug candidates following negative results, according to a Thursday Australian bourse filing.

The company will be reducing its workforce by about 65% to cut costs while retaining a limited number of employees to ensure compliant termination of clinical trial activities and oversee administrative operations, the filing added.

The company expects the workforce reduction to take effect from May 1 with one-off costs of about $4.5 million, resulting reduction in monthly employee costs of $1 million.

The company sees unaudited cash and cash equivalents of $100 million at the end of March.

The company said its ability to continue as a going concern remains materially uncertain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2526324926?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-10 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526324926","market":"sh","top_or_hot":-1,"title":"Opthea Cuts 65% Staff, Terminates Drug Trials","media":"MT Newswires Live","content":"<html><body><p> Opthea (ASX:OPT) has terminated phase three clinical trials for two of its drug candidates following negative results, according to a Thursday Australian bourse filing.</p><p>The company will be reducing its workforce by about 65% to cut costs while retaining a limited number of employees to ensure compliant termination of clinical trial activities and oversee administrative operations, the filing added.</p><p>The company expects the workforce reduction to take effect from May 1 with one-off costs of about $4.5 million, resulting reduction in monthly employee costs of $1 million.</p><p>The company sees unaudited cash and cash equivalents of $100 million at the end of March.</p><p>The company said its ability to continue as a going concern remains materially uncertain.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opthea Cuts 65% Staff, Terminates Drug Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpthea Cuts 65% Staff, Terminates Drug Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-10 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Opthea (ASX:OPT) has terminated phase three clinical trials for two of its drug candidates following negative results, according to a Thursday Australian bourse filing.</p><p>The company will be reducing its workforce by about 65% to cut costs while retaining a limited number of employees to ensure compliant termination of clinical trial activities and oversee administrative operations, the filing added.</p><p>The company expects the workforce reduction to take effect from May 1 with one-off costs of about $4.5 million, resulting reduction in monthly employee costs of $1 million.</p><p>The company sees unaudited cash and cash equivalents of $100 million at the end of March.</p><p>The company said its ability to continue as a going concern remains materially uncertain.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPT.AU","symbol_name":"OPTHEA LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2526324926","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526324926","pubTimestamp":1744247818,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Opthea  has terminated phase three clinical trials for two of its drug candidates following negative results, according to a Thursday Australian bourse filing.The company will be reducing its workforce by about 65% to cut costs while retaining a limited number of employees to ensure compliant termination of clinical trial activities and oversee administrative operations, the filing added.The company expects the workforce reduction to take effect from May 1 with one-off costs of about $4.5 million, resulting reduction in monthly employee costs of $1 million.The company sees unaudited cash and cash equivalents of $100 million at the end of March.The company said its ability to continue as a going concern remains materially uncertain.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPT.AU":"OPTHEA LTD","BK7508":"医药生物股","BK7067":"生物科技","BK4139":"生物科技"},"translate_title":"Opthea裁员65%，终止药物试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPT.AU":0.9,"OPT":1},"content_text":"Opthea (ASX:OPT) has terminated phase three clinical trials for two of its drug candidates following negative results, according to a Thursday Australian bourse filing.The company will be reducing its workforce by about 65% to cut costs while retaining a limited number of employees to ensure compliant termination of clinical trial activities and oversee administrative operations, the filing added.The company expects the workforce reduction to take effect from May 1 with one-off costs of about $4.5 million, resulting reduction in monthly employee costs of $1 million.The company sees unaudited cash and cash equivalents of $100 million at the end of March.The company said its ability to continue as a going concern remains materially uncertain.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2526324926","isCrawlerRequest":true}